Abstract 60P
Background
The PI3K/AKT/mTOR pathway plays a major role in melanoma pathogenesis and is also involved in resistance to targeted therapies (TT). The mTORC2 complex plays an important role in this pathway allowing activation of AKT and contributes to the development of BRAF-mutated (BRAFm) melanomas and their resistance to treatments. Once activated, AKT phosphorylates several effector proteins, thus regulating multiple key cellular processes, including proliferation, survival, motility, metabolism and angiogenesis.The goal of our project is to study this complex in melanoma in order to target it specifically. For this purpose, we are focusing more particularly on one principal protein of this complex: SIN1 (also called MAPKAP1) involved in the stabilizing of mTORC2 complex, in its substrate’s specificity, and a major player in the total activation of AKT.
Methods
We are analysing SIN1 expression, by quantitative RT-PCR and IHC and its interaction with other proteins, by Proximity Ligation Assay (PLA), in situ in melanoma biopsies of the French national MELBASE cohort. We will correlate these results with clinico-biological data from MELBASE to determine if there is a diagnostic or prognostic value of these analyses. In a second step, we are mapping the minimal domain of SIN1/NRAS interaction by Peptide Array to develop cell-permeable peptides to inhibit NRAS/mTORC2 interaction. Furthermore, we are evaluating whether SIN1 has also functions independent of the mTORC2 complex in melanoma, by searching for other partners of SIN1 by PLA in melanoma lines.
Results
Our preliminary results show that mTORC2 interacts with NRAS in BRAFm melanoma and that inhibiting the NRAS/mTORC2 interaction reduces the proliferation of melanoma cell lines and in particular those resistant to TT. This leads us to develop inhibitors to specifically target resistant melanomas.
Conclusions
The results of this project will provide us a better understanding of the mTORC2 signalling pathway in the development of BRAFm melanoma and its response to TT. Given the lack of a specific mTORC2 inhibitor at this time, SIN1 could be an ideal therapeutic target to aim for mTORC2.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fondation ARC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74P - Tumor agnostic comparison of immunohistochemistry and next-generation sequencing in detecting ALK fusions and assessment of ALK tyrosine kinase inhibitor efficacy
Presenter: Monica Chen
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Target identification by TIME phenotypes
Presenter: Robert Seitz
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Prediction of response to palliative chemotherapy by circulating tumor DNA (ctDNA) kinetics in metastatic pancreatic cancer
Presenter: Patrick Kirchweger
Session: Cocktail & Poster Display session
Resources:
Abstract
77P - Impact of germline HLA genotypes on clinical outcomes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - High resolution in situ analysis reveals phenotypic and functional diversification within single pancreatic tumour ducts
Presenter: Ellis Michiels
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Implementing genomic profiling as standard-of-care for glioblastoma patients
Presenter: Vincent Fougner
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Cyclic fasting-mimicking diet as a strategy to improve the efficacy of standard antitumor therapies in cancer patients
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Evaluation of response-predictive biomarkers for lisavanbulin: A phase II study in patients with recurrent glioblastoma
Presenter: Juanita Lopez
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Racial disparities in phase I lung cancer clinical trials
Presenter: Rohit Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials
Presenter: Antoine Mavrikios
Session: Cocktail & Poster Display session
Resources:
Abstract